Login to Your Account

Other News To Note

Wednesday, November 28, 2012

• Endocyte Inc., of West Lafayette, Ind., and Merck & Co. Inc., of Whitehouse Station, N.J., said the European Medicines Agency accepted for review a marketing authorization application for vintafolide (MK-8109/EC145) and the diagnostic imaging agent etarfolatide (EC20), which are in development for targeted treatment of folate-receptor-positive, platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription